ILMN vs. MTD: Illumina vs. Mettler-Toledo Stock Comparison

November 11, 2026

How do Illumina (ILMN) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Illumina (ILMN) and Mettler-Toledo (MTD) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Illumina (ILMN) and Mettler-Toledo (MTD)
Profile Item	ILMN	MTD
Name	Illumina Inc.	Mettler-Toledo International Inc.
Country/Region	United States	Switzerland
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
GICS Sub-Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
Market Capitalization	32.23 billion USD	34.25 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	July 28, 2000	November 14, 1997
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ILMN

MTD

GSPC

Illumina (ILMN) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Illumina (ILMN) and Mettler-Toledo (MTD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Illumina (ILMN) and Mettler-Toledo (MTD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Illumina (ILMN) and Mettler-Toledo (MTD)
Metric	ILMN	MTD
Total Return (1Y)	79.70%	21.58%
Total Return (3Y, Annualized)	28.16%	19.54%
Total Return (5Y, Annualized)	-10.65%	2.36%

Risk Profile

Drawdown History

ILMN

MTD

GSPC

Illumina (ILMN) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Illumina (ILMN) and Mettler-Toledo (MTD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Illumina (ILMN) and Mettler-Toledo (MTD)
Metric	ILMN	MTD
Volatility (1Y, Annualized)	48.47%	31.70%
Beta (5Y)	1.46	1.15
Max Drawdown (5Y)	-82.95%	-43.47%
Avg. Volume (3M)	2.77M	197.80K

Risk-Adjusted Performance

Risk-Return Positioning

ILMN and MTD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Illumina (ILMN) and Mettler-Toledo (MTD)
Metric	ILMN	MTD
Sharpe Ratio (1Y)	1.56	0.55
Sortino Ratio (1Y)	2.25	0.75

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Illumina (ILMN) earns 32.39% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.39%

Max: 109.18%
ILMN: 32.39%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
MTD: --

Illumina (ILMN) vs. Mettler-Toledo (MTD): MTD does not report ROE, so it has no value marker; ILMN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Both Illumina (ILMN) at 19.72% and Mettler-Toledo (MTD) at 22.25% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.72%

ILMN: 19.72%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.25%

MTD: 22.25%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Illumina (ILMN) vs. Mettler-Toledo (MTD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Illumina (ILMN) at 20.02% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max: 83.12%
ILMN: 20.02%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.70%

Max: 83.12%
MTD: 28.70%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Illumina (ILMN) vs. Mettler-Toledo (MTD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Illumina (ILMN) and Mettler-Toledo (MTD)
Metric	ILMN	MTD
ROE (TTM)	32.39%	--
ROA (TTM)	8.32%	20.09%
Net Margin (TTM)	19.72%	22.25%
Operating Margin (TTM)	20.02%	28.70%
Gross Margin (TTM)	67.68%	59.16%

Growth

Revenue Growth

Mettler-Toledo (MTD) at 3.98% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Illumina (ILMN) vs. Mettler-Toledo (MTD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Mettler-Toledo (MTD) reports EPS growth of 3.88%, ranked against its industry; Illumina (ILMN) has no EPS growth figure this period.

Illumina (ILMN) vs. Mettler-Toledo (MTD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Illumina (ILMN) and Mettler-Toledo (MTD)
Metric	ILMN	MTD
Revenue Growth (YoY)	-0.66%	3.98%
Revenue Growth (3Y CAGR)	-1.78%	0.90%
EPS Growth (YoY)	--	3.88%
EPS Growth (3Y CAGR)	--	3.06%

Financial Strength

Current Ratio (MRQ)

Illumina (ILMN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Mettler-Toledo (MTD) at 1.10 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MTD.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max: 25.13
Q3: 12.13
Median: 5.52
ILMN: 2.63
Q1: 2.47
Min: 0.10

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.10

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MTD: 1.10
Min: 0.10

Illumina (ILMN) vs. Mettler-Toledo (MTD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but MTD is more stretched: Illumina (ILMN) at 0.74 sits in the higher-leverage quartile and Mettler-Toledo (MTD) at 26.06 is above its industry benchmark range.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.74

Max: 1.42
ILMN: 0.74
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.06

MTD: 26.06
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Illumina (ILMN) vs. Mettler-Toledo (MTD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Illumina (ILMN) and Mettler-Toledo (MTD)
Metric	ILMN	MTD
Current Ratio (MRQ)	2.63	1.10
Debt / Equity (MRQ)	0.74	26.06
Net Debt / EBITDA	0.85	1.58

Dividends

Dividend Yield (TTM)

Neither Illumina (ILMN) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Illumina (ILMN) vs. Mettler-Toledo (MTD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Illumina (ILMN) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Illumina (ILMN) vs. Mettler-Toledo (MTD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Illumina (ILMN) and Mettler-Toledo (MTD)
Metric	ILMN	MTD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Both Illumina (ILMN) at 36.68 and Mettler-Toledo (MTD) at 37.38 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.68

Max: 85.34
Q3: 43.46
ILMN: 36.68
Median: 26.69
Q1: 13.30
Min: 0.07

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.38

Max: 85.34
Q3: 43.46
MTD: 37.38
Median: 26.69
Q1: 13.30
Min: 0.07

Illumina (ILMN) vs. Mettler-Toledo (MTD): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Illumina (ILMN) at 7.10 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.10

Max: 58.18
Q3: 25.77
Median: 7.30
ILMN: 7.10
Q1: 3.01
Min: 0.01

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 58.18
Q3: 25.77
MTD: 8.16
Median: 7.30
Q1: 3.01
Min: 0.01

Illumina (ILMN) vs. Mettler-Toledo (MTD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Illumina (ILMN) at 10.30 sits in the upper P/B ratio quartile, and Mettler-Toledo (MTD) at 442.71 prices even higher, above its industry range.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.30

Max: 13.53
ILMN: 10.30
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

442.71

MTD: 442.71
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Illumina (ILMN) vs. Mettler-Toledo (MTD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Illumina (ILMN) and Mettler-Toledo (MTD)
Metric	ILMN	MTD
P/E Ratio (TTM)	36.68	37.38
P/S Ratio (TTM)	7.10	8.16
P/B Ratio (MRQ)	10.30	442.71
Free Cash Flow Yield (TTM)	2.67%	1.97%